Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:42:55.422Z.
Consensus retrieved: 2026-10-06T14:22:09.198Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:42:55.422Z.
Quote observation: 2026-10-06T15:40:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8656b7a9da6ad27e4e3bee00a1f051c5b9ad9ad1f17b43070ca9e23e03b297bf
Forward PE Ratio (N/A) = Dated Quote Price ($26.21) / Consensus Forward EPS ($-5.57)
FORWARD PE RATIO
N/A
Neurogene Inc.
Market Cap
$414.19M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Neurogene Inc. (NGNE) | $414.19M | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $414.54M | N/A |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $417.95M | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $409.89M | N/A |
| Carlsmed, Inc. (CARL)vs › | $404.78M | N/A |
| Prothena Corporation plc (PRTA)vs › | $424.30M | 73.68 |
| Myriad Genetics, Inc. (MYGN)vs › | $402.83M | N/A |
| MapLight Therapeutics, Inc. (MPLT)vs › | $397.92M | N/A |
| NeoGenomics, Inc. (NEO)vs › | $437.59M | 93.20 |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $390.00M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $26.21, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-5.57 | $-5.94 – $-5.22 | 5 | n/m |
| 2027-12-31 | $-5.41 | $-7.22 – $-4.31 | 4 | n/m |
| 2028-12-31 | $-4.31 | $-7.32 – $1.80 | 5 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
